Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

News SummaryMost relevantAll newsSector newsTweets

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
08/22 DR REDDY LABORATORIES : Announces the Out-Licensing of DFD-06 to Encore Dermatol..
08/19 INDIAN ADRS : ICICI Bank ends down by 1%
08/16 DR REDDY LABORATORIES : Advice and Dissent
08/14 Lundin Law PC Announces an Investigation of Dr. Reddy’s Laboratories Li..
08/11 Khang & Khang LLP Announces an Investigation of Dr. Reddy’s Laboratorie..
08/11 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Dr. Reddy&rsq..
08/11 Goldberg Law PC Announces an Investigation of Dr. Reddy’s Laboratories ..
08/11 ELITE PHARMACEUTICALS INC. : Reports Financial Results for the First Quarter of ..
08/10 Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation ..
08/10 Rosen Law Firm Announces Investigation of Securities Claims Against Dr. Reddy..
More news
News from SeekingAlpha
08/22 Dr. Reddy's out-licenses steroid DFD-06 to Encore Dermatology for up to $32.5..
08/14 THE FISH MARKET : What Is Amarin Worth?
08/10 Perrigo Q2 beat lifts generics
08/09 Generic drug firms under pressure after soft guidance from Mylan
08/05 Indian Portfolio Exposure - Tricky But Possible
Financials ( INR)
Sales 2018 151 163 M
EBIT 2018 17 717 M
Net income 2018 14 152 M
Debt 2018 24 085 M
Yield 2018 0,95%
P/E ratio 2018 22,75
P/E ratio 2019 15,06
EV / Sales 2018 2,34x
EV / Sales 2019 2,04x
Capitalization 329 085 M
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Technical analysis trends DR.REDDY'S LABORATORIES LT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 40
Average target price 2 556  INR
Spread / Average Target 29%
EPS Revisions
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.83%358 180
NOVARTIS7.89%216 850
ROCHE HOLDING LTD.3.78%215 061
PFIZER2.06%195 090